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OBJECTIVE: To evaluate the quality of life for persons affected by age-related macular degeneration that results in monocular
or binocular legal blindness.
METHODS: An analytic transversal study using the National Eye Institute Visual Functioning Questionnaire (NEI VFQ-25) was
performed. Inclusion criteria were persons of both genders, aged more than 50 years old, absence of cataracts, diagnosis of age-
related monocular degeneration in at least one eye and the absence of other macular diseases. The control group was paired by
sex, age and no ocular disease.
RESULTS: Group 1 (monocular legal blindness) was composed of 54 patients (72.22% females and 27.78% males, aged 51 to 87
years old, medium age 74.61 ± 7.27 years); group 2 (binocular legal blindness ) was composed of 54 patients (46.30% females and
53.70% males aged 54 to 87 years old, medium age 75.61 ± 6.34 years). The control group was composed of 40 patients (40%
females and 60% males, aged 50 to 81 years old, medium age 65.65 ± 7.56 years). The majority of the scores were statistically
significantly higher in group 1 and the control group in relation to group 2 and higher in the control group when compared to
group 1.
CONCLUSIONS: It was evident that the quality of life of persons with binocular blindness was more limited in relation to
persons with monocular blindness. Both groups showed significant impairment in quality of life when compared to normal
persons.
KEY-WORDS: Retina/abnormalities. Macular degeneration/complications. Blindness/psychology. Vision. Llow/etiology. Quality
of life/psychology. Sickness impact profile.
INTRODUCTION
Age-related macular degeneration (AMD) is the main
cause of irreversible visual loss in individuals over the age
of 65, with an estimated prevalence of close to 10% in in-
dividuals between 65 and 75 years and 30% in individuals
over 75 years old.1,2 As a consequence of the increased life
expectancy of the world population, an increase in the
number of people with AMD is foreseen for this millen-
nium.3 Despite scientific advances and the discovery of new
drugs for the treatment of this disease, the therapies avail-
able to patients are somewhat limited and can only be ap-
plied in specific cases.4,5
The progressive deterioration of central vision that is
typical of this disease generally incapacitates the elderly,
hindering daily activities and, consequently, their quality
of life. Williams et al. applied evaluation instruments on
patients with AMD in order to establish scores related to
emotional and quality of life aspects and obtained results
similar to those found in diseases such as AIDS, chronic
obstructive pulmonary disease, cardiac disorders, melanoma
and leukemia. Furthermore, it was shown that most indi-
viduals with AMD reported the ocular disease as being their
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main limiting factor.6
The purpose of this study was to evaluate the quality
of life in patients with AMD with monocular or binocular
legal blindness with the 25-item National Eye Institute
Visual Function Questionnaire (NEI VFQ-25).
MATERIALS AND METHODS
A cross-sectional analytical study was conducted using
the NEI VFQ-25, which was applied as an interview. The
readily available sample consisted of patients seen at the
Retina Service of the Ophthalmology Clinic, University of
Sao Paulo General Hospital, from July to December 2006.
The following inclusion criteria were established in order
to obtain the sample: individuals of both sexes with ad-
vanced AMD and an absence of cataracts or other
maculopathies who were willing to be interviewed. The
control group consisted of individuals of both sexes who
had no ocular diseases and a visual acuity higher than or
equal to 20/40 in both eyes.
The respondents were classified into two groups accord-
ing to visual acuity (VA) in both eyes. Group 1 included
individuals with legal blindness in one eye (VA = 20/200
or worse) and a contralateral eye with VA = 20/60 or worse;
group 2 included individuals with legal blindness in both
eyes. The concept of blindness was the pattern used in the
United States of America.7 The “VA = 20/60 or worse” cri-
terion in the contralateral eye of the patients in Group 1
was established according to a previous study which re-
vealed that there is functional impairment at this acuity
level, such as difficulties reading and recognizing people.6
Before starting the interviews, study objectives and
methods were explained to the patients, who were assured
privacy and anonymity of the information they provided,
as well as the absence of damage and losses with regards
to the treatment offered at the ophthalmology clinic.
The NEI VFQ-25 is a closed questionnaire, whose va-
lidity and reliability has been proven in different
populations, and consists of 25 questions, grouped into 12
subdomains, including one or more questions each. The
questionnaire was applied in Portuguese, with the transla-
tion performed by Sant’Anna et al.8 The subdomains in-
clude general health, general vision, ocular pain, near ac-
tivities, far activities, social functioning, mental health, role
difficulties, dependence, driving difficulties, color vision
and peripheral vision. The scores range from 0 to 100,
where 0 represents a more severe visual impairment and
100, better vision. The score for each subdomain was cal-
culated by a simple mean of the corresponding answers;
the higher the score, the better the respondent’s quality of
life.9
Initially, all variables were descriptively analyzed. The
analysis of the quantitative variables included minimum and
maximum values, as well as the calculation of the mean,
standard deviation and median values. Absolute and rela-
tive frequencies were calculated for the qualitative vari-
ables. Student’s t test was used to analyze the hypothesis
of equality of means among the groups, and the Mann-
Whitney’s nonparametric test was used when the assump-
tion of data normality was rejected. In order to test the
groups’ homogeneity with regards to proportions, we ap-
plied the chi-squared test or Fischer’s exact test (for ex-
pected frequencies of less than 5). The level of significance
used for the tests was of 5%.10
The study was previously approved by the Ethics Com-
mission of the University of Sao Paulo General Hospital,
and all patients signed an Informed Consent Form.
RESULTS
The sample was comprised of 108 patients, 54 each for
groups 1 and 2. In group 1, 72.22% were women, and
27.78% were men; they were between the ages of 51 and
87, with a mean age of 74.61 ± 7.27 years. In group 2,
46.30% were women, and 53.70% were men; they were
between the ages of 54 and 87, with a mean age of 75.61
± 6.34 years. The sociodemographic characteristics of both
groups are shown in Table 1. The control group consisted
in 40 patients, 40% women and 60% men, between the ages
of 50 and 81; the mean age was 65.65 ± 7.56 years.
The groups only showed a significant difference regard-
ing gender distribution. When groups 1 and 2 were com-
pared to the control group, it was evident that the age of
those in the control group was significantly lower. No other
differences were observed.
All of the NEI VFQ – 25 subdomain scores with the
respective comparative statistical analyses between groups
are presented in Tables 2, 3 and 4. Most of the scores were
significantly higher in group 1 and the control group than
in group 2; scores were also significantly higher in the con-
trol group when compared to group 1.
DISCUSSION
The NEI VFQ – 25 is an instrument for the psychomet-
ric measurement of an individual’s quality of life that is
used to assess patients with ocular diseases leading to poor
vision.11-14 The questionnaire comprises items addressing
aspects such as physical, mental and social well-being, as
well as their consequences for the patient’s health status;
it has been validated in individuals with a variety of chronic
ocular diseases, such as AMD, glaucoma, diabetic retin-
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opathy, cataracts and cytomegalovirus retinitis.9
Previous studies have shown that individuals with AMD
are susceptible to depression, social isolation, emotional
stress, as well as feelings of fear, frustration and sad-
ness.4,11,15 This occurs because most of those in the age
group affected by the disease are retired and usually in-
dulge in activities that require good eyesight, such as read-
ing, watching TV, playing cards and sewing. In addition
to these mental problems, these patients become more sus-
ceptible to falls, which increases the risk of fractures due
to poor vision.16 Furthermore, the consequences of AMD
in daily activities, concerning the individual’s social and
emotional aspects, are precariously described in the litera-
ture.6,17 In the national literature, we found no register of
studies on the impact of AMD on patients’ lives.
Using the NEI VFQ – 25, Varma et al. observed that
individuals with moderate or serious visual impairments
(VA = 20/80 or worse) in both eyes, compared to those with
moderate bilateral impairments (VA = 20/40 – 20/60) or
unilateral impairment, had difficulties with visual function,
Table 2 - Comparison of the NEI VFQ – 25 subdomain
scores based on the responses of patients with age-related
macular degeneration and either monocular (group 1) or
binocular (group 2) legal blindness at the University of Sao
Paulo General Hospital in 2006
Subdomain Group 1* Group 2* p**
General health  39.81 ± 19.13  30.55 ± 21.53  0.023
General vision  58.51 ± 14.97  33.33 ± 16.48  < 0.001
Ocular pain  89.12 ± 13.95  78.70 ± 17.61  0.001
Near activities  68.67 ± 17.35  24.07 ± 17.03  < 0.001
Distance activities  66.82 ± 18.34  25.77 ± 16.92  < 0.001
Social functioning  88.19 ± 17.74  57.40 ± 32.62  < 0.001
Mental health  73.03 ± 18.28  36.92 ± 16.25  < 0.001
Role difficulties  65.04 ± 23.83  27.08 ± 17.80  < 0.001
Dependency  72.99 ± 23.40  38.27 ± 21.32  < 0.001
Color vision  91.66 ± 18.17  68.51 ± 26.68  < 0.001
Peripheral vision  79.62 ± 18.85  51.38 ± 27.65  < 0.001
* Mean ± standard deviation
** Mann-Whitney’s nonparametric test. Significance level of 0.05
Table 1 - Sociodemographic characteristics of patients with age-related macular degeneration with monocular (Group 1)
and binocular (Group 2) legal blindness at the University of Sao Paulo General Hospital in 2006.
Characteristics Group 1 Group 2 p
Age 74. 61 years ±7.27 (SD) 75.61 years ± 6.34 (SD) 0.448*
Sex n  (%) n  (%) 0.006
Female 39 72.22 25 46.30
Male 15 27.78 29 53.70
Education 0.874**
Primary 32 59.26 35 64.81
Secondary 14 25.93 11 20.37
Superior  5 9.26  4 7.41
Did not study  3 5.56  4 7.41
Marital Status 0.771**
Married 29 53.70 26 48.15
Widow 25 46.30 26 48.15
Single - -  1 1.85
Divorced - -  1 1.85
Remunerated work 1.000**
Yes  3 5.56  3 5.56
No 51 94.44 51 94.44
Reasons for not engaging in remunerated work  n = 51 0.229**
Retired 30 58.82 36 70.59
Pensioner 19 37.25 12 23.53
Unable to  1 1.96  - -
Cannot find a job  1 1.96  3 5.88
n = 108; *Student’s t test; **Fischer’s exact test. Significance level of 0.05
Table 3 - Comparison of the NEI VFQ – 25 subdomain
scores based on the responses of patients with age-related
macular degeneration and monocular (group 1) legal
blindness and the control group at the University of Sao
Paulo General Hospital in 2006
Subdomain Group 1* Control Group* p**
General health 39.81 ± 19.13 50.62 ± 20.79 0.0165
General vision 58.51 ± 14.97 78.50 ± 12.31 < 0.001
Ocular pain 89.12 ± 13.95 95.54 ± 4.81 0.0050
Near activities 68.67 ± 17.35 94.87 ± 6.68 < 0.001
Distance activities 66.82 ± 18.34 94.29 ± 7.75 < 0.001
Social functioning 88.19 ± 17.74 97.56 ± 0.00 0.0013
Mental health 73.03 ± 18.28 96.30 ± 1.92 < 0.001
Role difficulties 65.04 ± 23.83 97.56 ± 0.00 < 0.001
Dependency 72.99 ± 23.40 97.56 ± 0.00 < 0.001
Color vision 91.66 ± 18.17 100.00 ± 0.00 0.0925
Peripheral vision 79.62 ± 18.85 99.37 ± 3.95 < 0.001
* Mean ± standard deviation
** Mann-Whitney’s nonparametric test. Significance level of 0.05
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affecting near and far activities, mental health and depend-
ency. The low scores related to dependence and mental
health proved how much bilateral impairment affects the
individual, resulting in loss of independence and increased
levels of anxiety.13 Other authors showed that the conse-
quences of visual loss from AMD mainly affect the patient’s
mental health.6,15,18 Brody et al. indicated that depression
due to ocular disease is a significant problem.11
Based on the subdomains evaluated, the present study
showed that the scores of group 1 were significantly higher
than those of group 2, which suggests that quality of life
is more affected by binocular, as compared to monocular,
blindness. Nevertheless, both groups had lower scores when
compared to normal individuals, suggesting that a reduc-
tion of visual acuity, such as legal blindness in one eye and
subnormal vision in the other (group 1) or legal blindness
in both eyes (group 2), significantly affects quality of life.
With the exception of the “color vision” score, we observed
that the scores of normal individuals were significantly
higher than those of group 1; and all scores were higher
than those of Group 2, which suggests that AMD worsens
quality of life, whether it manifests as monocular or as bin-
ocular blindness. The subdomain “driving difficulties” was
not addressed because it was not a part of the daily lives
of the studied sample. Only a minority of the respondents
mentioned this activity, which made it impossible to per-
form comparative analyses.
An important limitation of this study was that it did not
analyze the time since disease onset because patients with
sudden visual impairment (secondary to neovascular mem-
brane) may be more affected, psychologically, than those
with a slow onset (secondary to geographic atrophy). Fur-
thermore, the sociocultural profile of the sample, compris-
ing patients seen at a university hospital, may interfere with
the results, although there was no difference between the
studied groups.
AMD affects the quality of life of the elderly, and stud-
ies should be developed, not only to address the pathophysi-
ological aspects of the disease but also to develop psycho-
social treatments. Such improvements should focus on the
prevention of mental problems, such as depression in the
elderly, and should orient patients on how to deal with the
limitations imposed by the disease.
Table 4 - Comparison of the NEI VFQ – 25 subdomain
scores based on the responses of patients with age-related
macular degeneration and legal binocular (group 2) blindness
and the control group at the University of Sao Paulo General
Hospital in 2006
Subdomain Group 2* Control Group* p**
General health 30.55 ± 21.53 50.62 ± 20.79 < 0.001
General vision 33.33 ± 16.48 78.50 ± 12.31 < 0.001
Ocular pain 78.70 ± 17.61 95.54 ± 4.81 < 0.001
Near activities 24.07 ± 17.03 94.87 ± 6.68 < 0.001
Distance activities 25.77 ± 16.92 94.29 ± 7.75 < 0.001
Social functioning 57.40 ± 32.62 97.56 ± 0.00 < 0.001
Mental health 36.92 ± 16.25 96.30 ± 1.92 < 0.001
Role difficulties 27.08 ± 17.80 97.56 ± 0.00 < 0.001
Dependency 38.27 ± 21.32 97.56 ± 0.00 < 0.001
Color vision 68.51 ± 26.68 100.00 ± 0.00 < 0.001
Peripheral vision 51.38 ± 27.65 99.37 ± 3.95 < 0.001
* Mean ± standard deviation
** Mann-Whitney’s nonparametric test. Significance level of 0.05
RESUMO
Marback RF, Maia Júnior OO, Morais FB, Takahashi WY.
Qualidade de vida de pacientes com Degeneração Macular
Relacionada à Idade com cegueira legal monocular e
binocular. Clinics. 2007; 62(5):573-8.
OBJETIVO: Avaliar a qualidade de vida de portadores de
degeneração macular relacionada à idade com cegueira le-
gal monocular e binocular.
MÉTODOS: Foi realizado estudo transversal analítico por
meio do questionário National Eye Institute Visual
Functioning Questionnaire (NEI VFQ-25). Os critérios de
inclusão foram: indivíduos de ambos os sexos, idade mai-
or que 50 anos, ausência de catarata, diagnóstico de dege-
neração macular relacionada à idade avançada em pelo
menos um dos olhos, sem outras maculopatias. O Grupo
Controle foi pareado por sexo, idade e sem doença ocular.
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RESULTADOS: O Grupo 1 (cegueira monocular) foi com-
posto por 54 pacientes (72,22% de mulheres e 27,78% de
homens, idade entre 51 e 87 anos, média de 74,61 anos ±
7,27 anos); o Grupo 2 (cegueira binocular), por 54 (46,30%
de mulheres e 53,70% de homens, idade entre 54 e 87 anos,
média de 75,61 anos ± 6,34 anos). O Grupo Controle foi
composto por 40 pacientes (40% de mulheres e 60% de
homens, idade entre 50 e 81 anos, média de 65,65 anos ±
7,56 anos). A maioria dos escores foi significativamente
maior no Grupo 1 e no Controle em relação ao Grupo 2 e
maior no Controle comparado ao Grupo 1.
CONCLUSÕES: Evidenciou-se que a qualidade de vida
de indivíduos com cegueira binocular foi mais limitada em
relação aos portadores de cegueira monocular. Quando
comparados com indivíduos normais, ambos os grupos ti-
veram prejuízo na qualidade de vida foi significativo.
UNITERMOS: Retina/Anormalidades. Degeneração.
Macular/complicações. Cegueira/Psicologia. Baixa Visão/
Etiologia. Qualidade de Vida/Psicologia. Perfil de Impacto
da Doença.
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